KR20040019043A - 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ - Google Patents

아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ Download PDF

Info

Publication number
KR20040019043A
KR20040019043A KR10-2004-7000093A KR20047000093A KR20040019043A KR 20040019043 A KR20040019043 A KR 20040019043A KR 20047000093 A KR20047000093 A KR 20047000093A KR 20040019043 A KR20040019043 A KR 20040019043A
Authority
KR
South Korea
Prior art keywords
water
atorvastatin
reaction mixture
hydrate
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7000093A
Other languages
English (en)
Korean (ko)
Inventor
엠사탸나라야나 레디
챠키람 나가라쥬
구디파티 스리니바술루
카타캄 시니바스
삭얌 라제스바 레디
Original Assignee
닥터 레디스 레보러터리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닥터 레디스 레보러터리즈 리미티드 filed Critical 닥터 레디스 레보러터리즈 리미티드
Publication of KR20040019043A publication Critical patent/KR20040019043A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-2004-7000093A 2001-07-30 2002-01-07 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ Ceased KR20040019043A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN620MA2001 2001-07-30
IN620/MAS/01 2001-07-30
PCT/US2002/000431 WO2003011826A1 (en) 2001-07-30 2002-01-07 Crystalline forms vi and vii of atorvastatin calcium

Publications (1)

Publication Number Publication Date
KR20040019043A true KR20040019043A (ko) 2004-03-04

Family

ID=35160889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2004-7000093A Ceased KR20040019043A (ko) 2001-07-30 2002-01-07 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ

Country Status (19)

Country Link
EP (2) EP1414796A1 (https=)
JP (1) JP2005500351A (https=)
KR (1) KR20040019043A (https=)
CN (1) CN100471836C (https=)
AU (1) AU2002255479B2 (https=)
BG (1) BG108518A (https=)
BR (1) BR0211488A (https=)
CA (1) CA2454500C (https=)
CZ (1) CZ2004126A3 (https=)
EE (1) EE200400048A (https=)
HR (1) HRP20040077A2 (https=)
IL (2) IL159626A0 (https=)
MX (1) MXPA04000889A (https=)
NO (1) NO20040390L (https=)
NZ (1) NZ530785A (https=)
PL (1) PL368647A1 (https=)
RU (1) RU2304139C2 (https=)
WO (1) WO2003011826A1 (https=)
ZA (1) ZA200400573B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
CN100406436C (zh) * 2002-02-15 2008-07-30 特瓦制药工业有限公司 阿托韦兹他汀半钙结晶以及制备阿托韦兹他汀半钙形式ix的方法
CN100379723C (zh) 2002-02-19 2008-04-09 特瓦制药工业有限公司 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
CA2508871C (en) * 2002-11-28 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
EP1424324A1 (en) * 2002-11-28 2004-06-02 Teva Pharmaceutical Industries Limited Crystalline form F of Atorvastatin hemi-calcium salt
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
ATE545629T1 (de) 2004-03-17 2012-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von atorvastatin- calcium in amorpher form
EP1761489A1 (en) * 2004-03-17 2007-03-14 Ranbaxy Laboratories Limited Crystalline form of atorvastatin hemi calcium
US8044086B2 (en) 2004-07-16 2011-10-25 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2701710C (en) 2004-07-20 2013-08-27 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CA2579997A1 (en) 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Process for preparing forms of atorvastatin calcium substantially free of impurities
AU2005298383A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006048894A1 (en) * 2004-11-05 2006-05-11 Morepen Laboratories Limited Novel crystalline forms of atorvastatin calcium and processes for preparing them.
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP2185527A2 (en) * 2007-07-11 2010-05-19 Actavis Group PTC EHF Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) * 2015-07-23 2015-10-21 青岛蓝盛洋医药生物科技有限责任公司 一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) * 2018-02-06 2020-10-02 上海应用技术大学 一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
KR100389518B1 (ko) 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en) 1997-05-02 1999-07-27 J.M. Huber Corporation Silica product for use in elastomers
HU226640B1 (en) 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
EP2206497A1 (en) * 1999-11-17 2010-07-14 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
EP1332130A4 (en) * 2000-11-03 2004-01-21 Teva Pharma HEMICALCIC ATORVASTATIN FORM VII
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (en) * 2000-12-27 2002-07-04 Teva Pharmaceutical Industries Ltd. Crystalline forms of atorvastatin
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)

Also Published As

Publication number Publication date
ZA200400573B (en) 2005-05-11
IL159626A0 (en) 2004-06-01
HRP20040077A2 (en) 2004-06-30
IL159626A (en) 2013-04-30
CN100471836C (zh) 2009-03-25
BR0211488A (pt) 2004-08-17
WO2003011826A1 (en) 2003-02-13
EP2292600A1 (en) 2011-03-09
CZ2004126A3 (cs) 2004-12-15
MXPA04000889A (es) 2004-06-03
CA2454500C (en) 2009-11-10
RU2304139C2 (ru) 2007-08-10
NZ530785A (en) 2005-10-28
NO20040390L (no) 2004-01-29
PL368647A1 (en) 2005-04-04
RU2004103470A (ru) 2005-06-20
JP2005500351A (ja) 2005-01-06
AU2002255479B2 (en) 2008-09-11
CA2454500A1 (en) 2003-02-13
EP1414796A1 (en) 2004-05-06
CN1537098A (zh) 2004-10-13
BG108518A (en) 2004-08-31
EE200400048A (et) 2004-04-15

Similar Documents

Publication Publication Date Title
KR20040019043A (ko) 아토바스탄틴 칼슘의 결정형 ⅵ 및 ⅶ
AU2002255479A1 (en) Crystalline forms VI and VII of atorvastatin clacium
FI94339B (fi) Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP5087193B2 (ja) 非晶質アトルバスタチンの調製方法
SK7212003A3 (en) Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy- 5-(1-methylethyl)-3-fenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1- heptanoic acid esters with calcium hydroxide
US20060122403A1 (en) Atorvastatin calcium form vi or hydrates thereof
US7074818B2 (en) Crystalline forms VI and VII of Atorvastatin calcium
KR101012917B1 (ko) 피롤 헵탄산 화합물의 신규한 결정형
KR100878140B1 (ko) 아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
EP1732886B1 (en) Polymorphs of atorvastatin tert.-butylester and use as intermediates for the preparation of atorvastatin
US20090082421A1 (en) Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof
JP2012031130A (ja) アトルバスタチンヘミカルシウム塩の新規な結晶形、その水和物、及びその製造方法
WO2006048894A1 (en) Novel crystalline forms of atorvastatin calcium and processes for preparing them.
KR101723783B1 (ko) 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
JPS61249970A (ja) 新規な置換２−（ｎ−アルキニル−ｎ−フエニルアミノ）イミダゾリン誘導体
ZA200501802B (en) Atorvastatin calcium form VI or hydrates thereof
AU2011211338A1 (en) Substituted pyrrole derivatives and their use as HMG-CO inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20061211

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071017

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080506

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071017

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080604

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080506

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20091030

Appeal identifier: 2008101005086

Request date: 20080604

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20080604

Effective date: 20091030

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20091030

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20080604

Decision date: 20091030

Appeal identifier: 2008101005086

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

PJ2001 Appeal

Patent event date: 20091030

Comment text: Trial Decision on Objection to Decision on Refusal

Patent event code: PJ20011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20101006

Appeal identifier: 2009201008904

Request date: 20091204

J302 Written judgement (patent court)

Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20091204

Effective date: 20101006

PJ1302 Judgment (patent court)

Patent event date: 20101011

Comment text: Written Judgment (Patent Court)

Patent event code: PJ13021S01D

Request date: 20091204

Decision date: 20101006

Appeal identifier: 2009201008904

Appeal kind category: Appeal against decision to decline refusal